Liu et al. performed a systematic review and meta-analysis that suggests that recombinant human interleukin-11 (rhIL-11), also known in the market as "Oprelvekin" and "Neumega," is effective and safe in the treatment of chemotherapy-induced thrombocytopenia in patients with acute leukemia. This evidence concerns the gene IL11 and Thrombocytopenia.